HCA Healthcare Inc. (HCA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HCA carries an RQD Score of 81 with a letter grade of A-, labeled "Roarable Buy — Superior Risk/Reward." The five pillars are:

• Fundamental Cash Engine: 18 / 20. Per the RQD rating, this pillar reflects ROIC of 18.9% and an FCF yield of 7.43%. For an investor, this is the strongest pillar and the core of the upside case: the business is generating returns above its capital base and converting a meaningful share of its market value into free cash flow.
• Whale 13F Flow: 15 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. The score is solid but not top-tier, suggesting institutional interest is supportive without being overwhelming.
• Insider Conviction: 18 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A high score here indicates insider and related trading activity that the rating treats as a positive signal.
• Macro Regime Fit: 14 / 20. Per the RQD rating, beta is 1.04 and the pillar reflects sector sensitivity. The beta near 1.0 implies the stock has tended to move roughly in line with the broad market, and this is the lowest-scoring pillar, indicating moderate rather than strong regime alignment.
• Forensic Balance Sheet: 16 / 20. Per the RQD rating, Altman Z is 3.68, Piotroski F is 8/9, and Debt/Equity is 0.85. These readings point to a financially sound balance sheet with a strong accounting-quality profile.

Taken together, the investor takeaway is that the rating's strongest support comes from cash generation and insider activity, with the balance sheet a close third. The main limiting factor is macro regime fit. Valuation is a tradeoff to weigh: per the market data, the stock trades at a P/E (TTM) of 15.3 and a forward P/E of 14.2, with an EV/EBITDA of 11.5, and it sits at $478.08 within a 52-week range of $353.99 to $556.52. A prospective investor should evaluate whether the cash-flow and balance-sheet strengths justify the current price relative to that range.

Per the SEC financials, revenue, operating income, net income, and free cash flow each increased across the three reported periods. Per the market data, operating margin is 10.9% and net margin is 9%, with ROIC of 18.9%. Per the RQD rating, the Altman Z-Score is 3.68 and the Piotroski F-Score is 8/9, and Debt/Equity is 0.85. Reported debt rose from $18243.0M in FY 2023 to $41603.0M in FY 2025, a trend a careful reader should note alongside the stable Debt/Equity reading, which the source does not reconcile against equity levels.

Per the recent news and catalysts section, six items were reported:

• RISK WATCH (RED): A Reuters report with the headline "HCA signals flat 2027 earnings as Medicaid payments drop; shares slide." This is the primary risk item in the wire, pointing to flat expected earnings and lower Medicaid payments.
• CATALYST (GREEN): A Motley Fool report, "2 Beaten-Down Healthcare Stocks to Buy and Hold for the Next Decade," which is flagged as a catalyst in the wire.
• MARKET WIRE (YELLOW): Several items, including a Yahoo Finance headline on expected earnings decline, a Cantor Fitzgerald rating reiteration citing stable labor, an Investor's Business Daily piece on HCA earnings, and a Yahoo Finance piece on a 96% run.

Per the Butterfly Supply-Chain Graph, there are no butterfly links and no proprietary signals. Not available in source data for proprietary supply-chain signal analysis.

Per the Butterfly Supply-Chain Graph, supply_chain is "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The investor-relevant ripple that the news wire does surface is the Medicaid payment reduction referenced in the RED-flagged Reuters item, which bears on reimbursement for a hospital operator; the source does not quantify its effect. Not available in source data for further supply-chain or sector correlation detail.

• What are the company's products, customer mix, and revenue sources beyond its sector classification?
• What is the magnitude of the Medicaid payment reduction referenced in the Reuters item, and how much of revenue is exposed to it?
• Why are EPS values reported as N/A for all three periods when net income is available?
• What is the source of the $1040.0M cash figure for FY 2025 relative to the debt increase to $41603.0M?
• Who are the institutional holders and insiders, and what are their positions?